http://www.accriva.com/uploads/assets/Press-Release-Issued-by-Accriva-January-20-2017-FINAL.pdf
Accriva Diagnostics, a Warburg Pincus portfolio company, announced today the definitive agreement with Werfen, a privately held medical diagnostics firm headquartered in Barcelona, Spain, and its subsidiary Instrumentation Laboratory (IL) headquartered in Bedford, MA, whereby Werfen and IL have acquired all shares of Accriva. The transaction was successfully closed on January 19, 2017. The Accriva portfolio, including globally recognized point-of-care (POC) diagnostic products for coagulation and anti-platelet therapy response, will allow IL to establish a market-leading position in hospital-based POC Hemostasis testing, expand its position in POC Critical Care testing and complement its leadership in the Hemostasis Laboratory segment. “We are proud of the value we have created,” said Scott Cramer, President and CEO of Accriva Diagnostics. “With our third consecutive year of record sales, significant operational efficiencies and new product pipeline, we foresee significant growth ahead. Now, the tremendous resources, expertise and global reach of Werfen and IL will accelerate this trajectory even further.” Accriva Diagnostics will become part of IL, a Werfen company, and continue operating out of its existing San Diego, CA facility, which currently employs approximately 460 employees. “The acquisition of Accriva strengthens our leadership in Hemostasis, Critical Care and Patient Blood Management testing,” said Ramon Benet, CEO at IL. “We see great synergy between our organizations and look forward to further impacting positive clinical outcomes and reducing healthcare costs in point-of-care testing with the breadth of this comprehensive portfolio.”